AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Major Depressive Disorder (MDD): Reboxetine mesylate is used to alleviate symptoms of depression, including persistent sadness, loss of interest or pleasure in activities, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, and difficulty concentrating.
Mechanism of Action: Reboxetine works by inhibiting the reuptake of norepinephrine (noradrenaline) in the brain. By blocking the reuptake transporter, it increases the concentration of norepinephrine in the synaptic cleft, thereby enhancing neurotransmission and potentially improving mood.
Efficacy: Clinical studies have shown that reboxetine mesylate can be effective in the treatment of depression. However, its efficacy may vary among individuals, and it may take several weeks for the full therapeutic effects to be realized.
Side Effects: Like all medications, reboxetine mesylate can cause side effects. Common side effects may include dry mouth, constipation, nausea, dizziness, headache, increased heart rate, sweating, and sexual dysfunction. These side effects are generally mild to moderate in nature and often improve with continued use or dosage adjustment.
Cardiovascular Effects: Reboxetine mesylate may have effects on the cardiovascular system, including increased heart rate and blood pressure. Patients with pre-existing cardiovascular conditions should use reboxetine with caution and under the supervision of a healthcare provider.
Withdrawal Symptoms: Abrupt discontinuation of reboxetine mesylate may lead to withdrawal symptoms, including flu-like symptoms, agitation, anxiety, irritability, insomnia, and dizziness. It is recommended to gradually taper the dose under medical supervision when discontinuing treatment.
Drug Interactions: Reboxetine mesylate may interact with other medications, particularly those that affect serotonin levels or have effects on the cardiovascular system. It is essential to inform healthcare providers about all medications, including prescription, over-the-counter, and herbal supplements, before starting reboxetine therapy.
Monitoring: Patients prescribed reboxetine mesylate should be monitored regularly by their healthcare provider to assess treatment response, monitor for side effects, and adjust dosage as necessary.
Suicidal Thoughts: As with other antidepressant medications, reboxetine mesylate may increase the risk of suicidal thoughts or behavior, particularly in children, adolescents, and young adults. Patients and caregivers should be vigilant for changes in mood or behavior and seek medical attention if concerning symptoms arise.
Individual Variation: The response to reboxetine mesylate may vary among individuals, and not all patients will experience the same benefits or side effects. Healthcare providers should tailor treatment to each patient's specific needs and closely monitor their response to therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Lactobacillus acidophilus | Reduces |
| species | Lactobacillus crispatus | Reduces |
| species | Lactobacillus gasseri | Reduces |
| species | Lactobacillus helveticus | Reduces |
| species | Lactobacillus jensenii | Reduces |
| species | Lactobacillus johnsonii | Reduces |
| species | Lactobacillus kefiranofaciens | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.5 | 1.2 | -1.4 |
| ADHD | 0 | 1.2 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.5 | -0.5 | |
| Allergies | 0.2 | 1.2 | -5 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.2 | 1.4 | -6 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.8 | 1 |
| Ankylosing spondylitis | 0.3 | 0.8 | -1.67 |
| Anorexia Nervosa | 0.2 | 0.5 | -1.5 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 1.2 | -1.2 | |
| Atherosclerosis | 0.5 | 0.2 | 1.5 |
| Atrial fibrillation | 1 | 1 | |
| Autism | 2 | 3.2 | -0.6 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.5 | 0.5 | 0 |
| Brain Trauma | 0.5 | -0.5 | |
| Carcinoma | 0.1 | 0.1 | |
| Celiac Disease | 1.3 | 1 | 0.3 |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.3 | 1.9 | -5.33 |
| Chronic Kidney Disease | 0 | 1.4 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.3 | 0.33 |
| Chronic Urticaria (Hives) | 0.1 | 0.3 | -2 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.1 | 2 |
| Colorectal Cancer | 0.6 | 0 | 0 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 0 | 0 | 0 |
| COVID-19 | 1.6 | 3.2 | -1 |
| Crohn's Disease | 0.9 | 2.5 | -1.78 |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 2.5 | 2.4 | 0.04 |
| Dermatomyositis | 0.1 | 0.5 | -4 |
| Eczema | 0.6 | -0.6 | |
| Endometriosis | 0.7 | 1.1 | -0.57 |
| Eosinophilic Esophagitis | 0.7 | -0.7 | |
| Epilepsy | 0.8 | 1.5 | -0.88 |
| Fibromyalgia | 0.6 | -0.6 | |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1.1 | 0.27 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.3 | 2.67 |
| Generalized anxiety disorder | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.3 | 0 | 0 |
| Graves' disease | 0.7 | 0.7 | 0 |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.2 | 0.3 | -0.5 |
| Heart Failure | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.1 | 0.5 | -4 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 0 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.3 | -0.3 | |
| hyperglycemia | 1 | -1 | |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.9 | -3.5 |
| hypertension (High Blood Pressure | 0.8 | 0.8 | 0 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 1.1 | -1.1 | |
| Inflammatory Bowel Disease | 1.4 | 1.9 | -0.36 |
| Insomnia | 0.8 | 0.8 | 0 |
| Intelligence | 0 | 0 | |
| Intracranial aneurysms | 0.5 | -0.5 | |
| Irritable Bowel Syndrome | 1 | 2.3 | -1.3 |
| Juvenile idiopathic arthritis | 0.5 | -0.5 | |
| Liver Cirrhosis | 0.8 | 0.8 | 0 |
| Long COVID | 2.2 | 2.3 | -0.05 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.5 | -0.5 | |
| ME/CFS with IBS | 0.1 | 0.1 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.5 | 2.4 | -0.6 |
| Mood Disorders | 3.2 | 2.4 | 0.33 |
| multiple chemical sensitivity [MCS] | 1 | 1 | |
| Multiple Sclerosis | 1.5 | 2 | -0.33 |
| Multiple system atrophy (MSA) | 1 | 1 | |
| Neuropathy (all types) | 1.3 | 1.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.7 | -0.4 |
| Obesity | 1.3 | 1.4 | -0.08 |
| obsessive-compulsive disorder | 1.1 | 0.9 | 0.22 |
| Osteoarthritis | 0.1 | 0.5 | -4 |
| Osteoporosis | 0.5 | 1.3 | -1.6 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 1.4 | 1.8 | -0.29 |
| Polycystic ovary syndrome | 1.1 | 0.2 | 4.5 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Psoriasis | 1.6 | 0.4 | 3 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 1.3 | 0.08 |
| Rosacea | 0 | 1 | 0 |
| Schizophrenia | 1.5 | 0.5 | 2 |
| scoliosis | 0 | 0.6 | 0 |
| Sjögren syndrome | 0.8 | 0 | 0 |
| Sleep Apnea | 0.5 | 0 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.5 | -4 |
| Stress / posttraumatic stress disorder | 0.7 | 0.9 | -0.29 |
| Systemic Lupus Erythematosus | 0.8 | 1.7 | -1.13 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.2 | 0.5 | -1.5 |
| Type 1 Diabetes | 1.2 | 1.6 | -0.33 |
| Type 2 Diabetes | 2.1 | 2.4 | -0.14 |
| Ulcerative colitis | 1.5 | 2 | -0.33 |
| Unhealthy Ageing | 1.3 | 0.4 | 2.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.